


AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) Compounds having an anti-parasitic, in particular antimalarial, activity characterized in that they correspond to general formula (I)



in which

- either X represents a group of formula (II)




where Z is a $-(\text{CH}_2)_m$ group, within 8 to 21,

$n = 0$ or 1

and $\text{Y}=\text{R}_3$,

- R_1 and R'_1 , identical to or different from one another, being chosen from H, alkyl, aryl, OH, O-alkyl, O-aryl, O-CO-alkyl, O-CO-aryl, O-CO-O(or S or NH)-alkyl, O-CO-O(or S or NH)-aryl, PO(O-alkyl or O-aryl)₂, CO-O-CH₂-aryl, cycloalkyl,
- R_2 and R'_2 , identical to or different from one another, being chosen from H, alkyl, CO-O-CH₂-aryl, CO-O-alkyl, cycloalkyl,

- R_3 and R'_3 , identical to or different from one another, representing H, alkyl, aryl, CO-O-alkyl, CO-O-aryl, COO-CH(R)-O-CO-alkyl, PO(O-alkyl or O-aryl or ONa)₂, CO-O-CH(R)-aryl,
- R being H or alkyl,
- or
- R_1 and R_2 , and/or R'_1 and R'_2 , or R_2 and R_3 and/or R'_2 and R'_3 , together form a heterocycle with the nitrogen atom or atoms to which they are respectively attached, or also,
- R_2 and R_3 and/or R'_2 and R'_3 can be the same substituent, double-bonded to the nitrogen, cyclized with, respectively, R_1 or R'_1 in order to form a heterocycle, if appropriate substituted by R_a , which is chosen from H, alkyl, alkyl substituted by 1, 2 or 3 halogen atoms, aryl, CO-O-alkyl (or aryl), -CO-OH, -CO-NH₂, -CN, -CO-NH-alkyl (or aryl), -CO-N-(alkyl)₂, nitrogenated and/or oxygenated -CO-heterocycle, NH(H or alkyl), N(alkyl)₂, nitrogenated and/or oxygenated heterocycle, -O-alkyl (or aryl), -O-CH₂-aryl, CH₂N[H, (H, alkyl), (dialkyl), aryl], nitrogenated and/or oxygenated -CH₂-heterocycle, CH₂-CO-OH,
- or $X = R_4$ and Y represents a group of formula (III)



with n and Z as defined above,


- R_1 and R'_1 , identical to or different from one another, being chosen from H, OH, O-alkyl, O-CO-O-alkyl (or aryl), O-CO-S-alkyl, O-CO-alkyl (or aryl), O-CO-NH-alkyl (or aryl),

R_1 and R'_1 , identical to or different from one another, being chosen from H, alkyl, aryl, OH, O-alkyl, O-aryl, O-CO-alkyl, O-CO-aryl, O-CO-O(or S or NH)-alkyl, O-CO-O(or S or NH)-aryl, PO(O-alkyl or O-aryl)₂, CO-O-CH₂-aryl, cycloalkyl,

- R_1 and R'_4 represent an H or alkyl, and
- R_2 and R'_2 , identical to or different from one another, being chosen from H, alkyl, CO-O-CH₂-aryl, CO-O-alkyl cycloalkyl, or
- R_1 and R_4 and/or R'_1 and R'_4 together form a $-(CH_2)_p$ group, p being an integer from 3 to 5, and R_2 and R'_2 representing H, or R_4 and R_2 and/or R'_4 and R'_2 together form a $-(CH_2)_p$ group, R_1 and R'_1 representing H, and the pharmacologically acceptable salts of these compounds.


2. (currently amended) Compounds according to claim 1, characterized in that

they correspond to formula (IV).



in which n, Z, R_1 , R'_1 , R_2 , R'_2 , R_3 and R'_3 are as defined in claim 1.

3. (currently amended) Compounds according to claim 2, characterized in that they correspond to formula (V):



in which Z, R₁, R'₁, R₂, R'₂, R₃ and R'₃ are as defined in claim 1.

4. (original) Compounds according to claim 3, characterized in that R₁, R'₁, R₂, R'₂, R₃ and R'₃ are independent of one another.

5. (original) Compounds according to claim 4, characterized in that R₁ and/or R'₁ are as defined above, but do not represent a hydrogen atom, whilst R₃ and/or R'₃, R₂ and/or R'₂, represent a hydrogen atom, R₁, R₂ and R₃.


6. (original) Compounds according to claim 5, characterized in that R₁ and/or R'₁, and R₂ and/or R'₂ represent a hydrogen atom, whilst R₃ and/or R'₃ are as defined above, but different from a hydrogen atom.

7. (original) Compounds according to claim 3, characterized in that


- R₁ and R₂, and/or R'₁ and R'₂, or
- R₂ and R₃, and/or R'₂ and R'₃, or

— R_1 , R_2 and R_3 and/or R'_1 , R'_2 and R'_3 together form a heterocycle.

8. (original) Compounds according to claim 7, characterized in that R_1 and R_2 as well as R'_1 and R'_2 form a heterocycle and correspond to formula (VI)



9. (original) Compounds according to claim 7, characterized in that they correspond to formula (VII)



10. (original) Compounds according to claim 8, characterized in that formula (VI) R_1 and R_2 and/or R'_1 and R'_2 together form an -O-CO-, O-SO-, O-CS, S-CO or -S-CS group, and R_3 and/or R'_3 represent a hydrogen atom.

11. (original) Compounds according to claim 8, characterized in that R_1 and R_2 , and/or R'_1 and R'_2 represent an optionally branched alkylene group and R_3 and/or R'_3


VIAL et al.

U.S. National Phase of PCT/FR2003/002283

represent -CO-O-alkyl (or aryl), -CO-O-CH₂-aryl, CO-O-CH(alkyl)-O-CO-alkyl, PO(O-alkyl or -aryl)₂, alkyl or H.


12. (original) Compounds according to claim 9, characterized in that R₁ and/or R'₁ represent a hydrogen atom, and R₂ and R₃, and/or R'₂ and/or R'₃ represent a - (CH₂)_p- group.

13. (original) Compounds according to claim 2, characterized in that R₂ and R₃ and/or R'₂ and R'₃ form the same substituent and form together with R₁ or respectively R'₁ a bis-oxadiazole of formula (VIII.)




in which R_a is as defined above.

14. (original) Compounds according to claim 1, characterized in that they correspond to formula (IX)



15. (original) Compounds according to claim 14, characterized in that Z = -
(CH₂)_m and n = 0, the compounds corresponding to the formula (X)




16. (original) Compounds according to claim 15, characterized in that the substituents are independent of one another.

17. (original) Compounds according to claim 16, characterized in that R₁ and R₄ and/or R'₁ and R'₄ are as defined above and R₂ and R'₂ represent a hydrogen atom.

18. (original) Compounds according to claim 16, characterized in that R₁ and R₄ and/or R'₁ and R'₄ together represent a -(CH₂)_p- group where p is an integer from 3 to 5 and R₂ and R'₂ represent H.

19. (original) Compounds according to claim 16, characterized in that R₁ and R'₁ represent H and R₄ and R₂ and/or R'₄ and R'₂ together represent a -(CH₂)_p- group where p is an integer from 3 to 5.

20. (original) Compound according to claim 16, characterized in that it corresponds to formula (XI)



21. (original) Process for obtaining carbamates and of N-phosphorylated derivatives of general formula (V), characterized in that it comprises the reaction in a diphasic medium of the bisamidine compounds of general formula (V) in which R_3 and $R'_3 = H$ with a C1- R_3 (or R'_3) derivative where R_3 and R'_3 are as defined above and different from H.

22. (original) Process for obtaining amidoxime derivatives of general formula (X), characterized in that it comprises the reaction in a basic medium of the bisamidoximes of general formula (X) in which R_1 and $R'_1 = OH$ and the appropriate reagent.

23. (original) Process according to claim 22, characterized in that in order to obtain compounds of general formula (VI) group a2 and (VIII) group a4 defined above, intramolecular cyclization of amidoxime or of amidoxime derivatives previously defined by general formula (V) group a1 is carried out in the presence of the appropriate reagent.

24. (currently amended) Pharmaceutical compositions, characterized in that they contain an effective quantity of at least one compound as defined in ~~any one of~~

~~claims 1 to 20~~ claim 1 in association with an inert pharmaceutical vehicle.

25. (original) Pharmaceutical compositions according to claim 24, characterized in that they can be administered by oral route, by injectable route, or also by rectal route.

26. (currently amended) Compositions according to claim 24 ~~or 25~~ for the treatment of infectious diseases, in particular malaria, ~~characterized in that they comprise an effective quantity of the compounds according to any one of claims 1 to 20.~~

27. (currently amended) Use of at least one compound according to ~~any one of~~ ~~claims 1 to 20~~ claim 1 in order to produce medicaments for the treatment of anti-parasitic diseases, in particular malaria.

28. (currently amended) Use of at least one compound according to ~~any one of~~ ~~claims 1 to 20~~ claim 1 in order to produce medicaments for the treatment of anti-parasitic diseases, in particular malaria and babesioses.